Despite a drop-off in deal numbers, 2019 was a great year for biopharma IP owners
Last year’s M&A and licensing figures suggest that there is a sellers' market in many types of life sciences assets
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.